New pill shows promise for stubborn depression
NCT ID NCT05066672
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called NV-5138 in 250 adults with treatment-resistant depression (depression that hasn't improved with standard treatments). Participants took either the drug or a placebo for several weeks. The main goal was to see if the drug reduces depression symptoms better than placebo, measured by a standard depression scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NV-5138 (also called SPN820), a drug that boosts a cell signaling pathway
What this could lead to
If it works, this could offer a new option for people with depression that hasn't responded to other treatments.
What could go wrong
This is a Phase 2 trial, so it's still early. The drug may not work better than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwest Clinical Research Center, Inc.
Bellevue, Washington, 98007, United States